Telmisartan/Hydrochlorothiazide in the Treatment of Hypertension

• Hajjar I , KotchenTA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000.JAMA290, 199–206(2003).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM , EvansJC, LevyD: Hypertension in adults across the age spectrum: current outcomes and control in the community.JAMA294, 466–472(2005).
   PubMed Web of Science ®Google Scholar
• Fagard RH : Epidemiology of hypertension in the elderly.Am. J. Geriatr. Cardiol.11, 23–28(2002).
   PubMedGoogle Scholar
• Guidelines Committee: 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053(2003).
   PubMed Web of Science ®Google Scholar
• Wang JG , StaessenJA, FranklinSS, FagardR, GueyffierF: Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome.Hypertension45, 907–913(2005).
   PubMed Web of Science ®Google Scholar
• Lewington S , ClarkeR, QizilbashN, PetoR, CollinsR: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.Lancet360, 1903–1913(2002).
   PubMed Web of Science ®Google Scholar
• Leeper SC : Aggressive hypertension management in patients of advancing and advanced age.South. Med. J.98, 805–808(2005).
   PubMed Web of Science ®Google Scholar
• Sacks FM , SvetkeyLP, VollmerWMet al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet.N. Engl. J. Med.344, 3–10(2001).
   PubMed Web of Science ®Google Scholar
• Simon G , CheslerE: Understanding and managing isolated systolic hypertension in the elderly.Am. J. Geriatr. Cardiol.7, 35–39(1998).
   PubMedGoogle Scholar
• Weber MA : Angiotensin II receptor blockers in older patients.Am. J. Geriatr. Cardiol.13, 197–205(2004).
   PubMedGoogle Scholar
• Lancaster KJ , Smiciklas-WrightH, Heller DA, Ahern FM, Jensen G: Dehydration in black and white older adults using diuretics. Ann. Epidemiol.13, 525–529(2003).
   PubMed Web of Science ®Google Scholar
• Poon IO , BraunU: High prevalence of orthostatic hypertension and its correlation with potentially causative medications among elderly veterans.J. Clin. Pharm. Ther.30, 173–178(2005).
   PubMed Web of Science ®Google Scholar
• Flockhart DA , Tanus-SantosJE: Implications of cytochrome P450 interactions when prescribing medication for hypertension.Arch. Intern. Med.162, 405–412(2002).
   PubMed Web of Science ®Google Scholar
• Miller NH , HillM, KottkeT, OckeneIS: The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals.Circulation95, 1085–1090(1997).
   PubMed Web of Science ®Google Scholar
• Rudd P : Clinicians and patients with hypertension: unsettled issues about compliance.Am. Heart J.130, 572–579(1995).
   PubMed Web of Science ®Google Scholar
• Kjellgren KI , AhlnerJ, DahlöfB, GillH, HednerT, SaljoR: Patients’ and physicians’ assessment of risks associated with hypertension and benefits from treatment.J. Cardiovasc. Risk5, 161–166(1998).
   PubMedGoogle Scholar
• Hughes CM : Medication non-adherence in the elderly: how big is the problem?Drugs Aging21, 793–811(2004).
   PubMed Web of Science ®Google Scholar
• Chobanian AV , BakrisGL, BlackHRet al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.JAMA289, 2560–2572(2003).
   PubMed Web of Science ®Google Scholar
• Dickerson LM , GibsonMV: Management of hypertension in older persons.Am. Fam. Physician71, 469–476(2005).
   PubMed Web of Science ®Google Scholar
• Franse LV , PahorM, Di Bari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension35, 1025–1030(2000).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288, 2981–2997(2002).
   PubMed Web of Science ®Google Scholar
• Whitworth JA : 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.J. Hypertens.21, 1983–1992(2003).
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr, Shykoff BE: Arterial stiffness: clinical relevance, measurement, and treatment. Rev. Cardiovasc. Med.2, 29–40(2001).
   PubMedGoogle Scholar
• Safar ME , BenetosA: Factors influencing arterial stiffness in systolic hypertension in the elderly: role of sodium and the renin–angiotensin system.Am. J. Hypertens.16, 249–258(2003).
   PubMed Web of Science ®Google Scholar
• Franklin SS , KhanSA, WongND, Larson MG, Levy D: Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation100, 354–360(1999).
   PubMed Web of Science ®Google Scholar
• Kannel WB : Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile.Am. Heart J.138(3 Pt 2), S205–S210 (1999).
   PubMed Web of Science ®Google Scholar
• Kannel WB : Risk stratification in hypertension: new insights from the Framingham Study.Am. J. Hypertens.13, S3–S10 (2000).
   PubMed Web of Science ®Google Scholar
• Rigaud AS , SeuxML, StaessenJA, BirkenhagerWH, ForetteF: Cerebral complications of hypertension.J. Hum. Hypertens.14, 605–616(2000).
   PubMed Web of Science ®Google Scholar
• Kario K , PickeringTG, UmedaYet al.: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study.Circulation107, 1401–1406(2003).
   PubMed Web of Science ®Google Scholar
• Perico N , CodreanuI, SchieppatiA, RemuzziG: The future of renoprotection.Kidney Int. Suppl.97, S95–S101 (2005).
   Google Scholar
• McInnes GT : The expanding role of angiotensin receptor blockers in the management of the elderly hypertensive.Curr. Med. Res. Opin.19, 452–455(2003).
   PubMed Web of Science ®Google Scholar
• Esposti LD , Di Martino M, Saragoni S et al.: Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J. Clin. Hypertens.6, 76–84(2004).
   PubMedGoogle Scholar
• Battershill AJ , ScottLJ: Telmisartan. A review of its use in the management of hypertension.Drugs66, 51–83(2006).
   PubMed Web of Science ®Google Scholar
• Ambrosioni E : Pharmacoeconomics of hypertension management: the place of combination therapy.Pharmacoeconomics19, 337–347(2001).
   PubMed Web of Science ®Google Scholar
• Neutel JM : Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management.Am. J. Hypertens.12(8 Pt 2), S73–S79 (1999).
   PubMed Web of Science ®Google Scholar
• Wienen W , EntzerothM, van Meel JCA et al.: A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc. Drug Rev.18, 127–156(2000).
   Google Scholar
• Wienen W , HauelN, van Meel JC, Narr B, Ries U, Entzeroth M: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol.110, 245–252(1993).
   PubMed Web of Science ®Google Scholar
• Unger T : The angiotensin type 2 receptor: variations on an enigmatic theme.J. Hypertens.17(12 Pt 2), 1775–1786(1999).
   PubMed Web of Science ®Google Scholar
• Schierok H , PairetM, HauelN, Wienen W: Effects of telmisartan on renal excretory function in conscious dogs. J. Int. Med. Res.29, 131–139(2001).
   PubMed Web of Science ®Google Scholar
• Wienen W , EntzerothM: Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR 277 in the rat.J. Hypertens.12, 119–128(1994).
   PubMed Web of Science ®Google Scholar
• Böhm M , LippoldtA, WienenW, Ganten D, Bader M: Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol. Cell. Biochem.163–164, 217–221 (1996).
   Web of Science ®Google Scholar
• Stangier J , Su C-APF, van Heiningen PN et al.: Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J. Cardiovasc. Pharmacol.38, 672–685(2001).
   PubMed Web of Science ®Google Scholar
• Mahmud A , FeelyJ: Arterial stiffness and the renin–angiotensin–aldosterone system.J. Renin Angiotensin Aldosterone Syst.5, 102–108(2004).
   PubMed Web of Science ®Google Scholar
• Asmar R , GosseP, TopouchianJ, N‘telaG, GrayS, DudleyA: Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension.J. Renin Angiotensin Aldosterone Syst.3, 176–180(2002).
   PubMed Web of Science ®Google Scholar
• Stangier J , SuCAPF, RothW: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.J. Int. Med. Res.28, 149–167(2000).
   PubMed Web of Science ®Google Scholar
• Stangier J , SchmidJ, TürckDet al.: Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers.J. Clin. Pharmacol.40, 1312–1322(2000).
   PubMed Web of Science ®Google Scholar
• Ebner T , HeinzelG, ProxA, BeschkeK, WachsmuthH: Disposition and chemical stability of telmisartan 1-O-acylglucuronide.Drug Metab. Dispos.27, 1143–1149(1999).
   PubMed Web of Science ®Google Scholar
• Neutel JM , SmithDH: Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension.Adv. Ther.15, 206–217(1998).
   Web of Science ®Google Scholar
• Brunner HR : The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.J. Hum. Hypertens.16(Suppl. 2), S13–S16 (2002).
   PubMed Web of Science ®Google Scholar
• Burnier M , MaillardM: The comparative pharmacology of angiotensin II receptor antagonists.Blood Press.10(Suppl. 1), 6–11(2001).
   PubMed Web of Science ®Google Scholar
• Unger T , KaschinaE: Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.Drug Saf.26, 707–720(2003).
   PubMed Web of Science ®Google Scholar
• Stangier J , SuCA, HendriksMGCet al.: The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers.J. Clin. Pharmacol.40, 1373–1379(2000).
   PubMed Web of Science ®Google Scholar
• Yong C -L, Dias VC, Stangier J: Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J. Clin. Pharmacol.40, 1323–1330(2000).
   PubMed Web of Science ®Google Scholar
• Stangier J , SuCA, BricklR, FrankeH, ThiessP: Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers.J. Clin. Pharmacol.40, 1365–1372(2000).
   PubMed Web of Science ®Google Scholar
• Stangier J , SuCA, SchöndorferG, RothW: Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers.J. Clin. Pharmacol.40, 1355–1364(2000).
   PubMed Web of Science ®Google Scholar
• McGill JB , ReillyPA: Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.Clin. Ther.23, 833–850(2001).
   PubMed Web of Science ®Google Scholar
• Fenton C , KeatingGM, ScottLJ: Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.Drugs63, 2013–2026(2003).
   PubMed Web of Science ®Google Scholar
• Gadegbeku CA , LeaJP, JamersonKA: Update on disparities in the pathophysiology and management of hypertension: focus on African Americans.Med. Clin. North Am.89, 921–933(2005).
   PubMed Web of Science ®Google Scholar
• McGill JB , ReillyPA: Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension.Clin. Cardiol.24, 66–72(2001).
   PubMed Web of Science ®Google Scholar
• Lacourcière Y , MartinK, on behalf of the Telmisartan Study Group: Comparison of a fixed-dose combination of telmisartan 40 mg plus hydrochlorothiazide 12.5 mg with telmisartan 40 mg in the control of mild-to-moderate hypertension. Am. J. Ther.9, 111–117(2002).
   PubMedGoogle Scholar
• Lacourcière Y , TytusR, O‘KeefeD, LenisJ, OrchardR, MartinK: Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy.J. Hum. Hypertens.15, 763–770(2001).
   PubMed Web of Science ®Google Scholar
• Freytag F , HolwerdaNJ, KarlbergBE, MeinickeTW, SchumacherH: Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety.Blood Press.11, 173–181(2002).
   PubMed Web of Science ®Google Scholar
• Lacourcière Y , Gil-ExtremeraB, Mueller O, Byrne M, Williams L: Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int. J. Clin. Pract.57, 273–279(2003).
   PubMed Web of Science ®Google Scholar
• Neutel JM , LittlejohnTW, ChrysantSG, SinghSA, on behalf of the Telmisartan Study Group: Telmisartan/hydrochlorothiazide in comparison with losartan/ hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens. Res.28, 555–563(2005).
   PubMed Web of Science ®Google Scholar
• Sharma A , DavidsonJ, GavinJ III, DeSousa B: Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension46, 898–899(2005).
   Web of Science ®Google Scholar
• Fogari R , PretiP, ZoppiAet al.: Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation.Am. J. Hypertens.18, 577–583(2005).
   PubMed Web of Science ®Google Scholar
• Fogari R , MugelliniA, ZoppiAet al.: Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients.J. Hum. Hypertens.20, 177–185(2006).
   PubMed Web of Science ®Google Scholar
• Karlberg BE , Lins L-E, Hermansson K, for the TEES Study Group: Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J. Hypertens.17, 293–302(1999).
   PubMed Web of Science ®Google Scholar
• Freytag F , SchellingA, MeinickeT, Deichsel G, for the THERESA (Telmisartan Hypertension Experience in a Randomized European Study versus Atenolol) Study Group: Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild-to-moderate hypertension: a randomized, multicenter study. Clin. Ther.23, 108–123(2001).
   PubMed Web of Science ®Google Scholar
• White WB , WeberMA, DavidaiG, Neutel JM, Bakris GL, Giles T: Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press. Monit.10, 157–163(2005).
   PubMed Web of Science ®Google Scholar
• Neldam S , for the ATHOS Group: Telmisartan + hydrochlorothiazide versus amlodipine + hydrochlorothiazide in older patients with predominantly systolic hypertension. J. Hypertens.23(Suppl. 2), S116 (2005).
   Web of Science ®Google Scholar
• Staessen JA , ThijsL, FagardRet al.: Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension.JAMA282, 539–546(1999).
   PubMed Web of Science ®Google Scholar
• Michel MC , BohnerH, KosterJ, Schafers R, Heemann U: Safety of telmisartan in patients with arterial hypertension. An open-label observational study. Drug Saf.27, 335–344(2004).
   PubMed Web of Science ®Google Scholar
• Beermann B , Groschinsky-GrindM: Pharmacokinetics of hydrochlorothiazide in man.Eur. J. Clin. Pharmacol.12, 297–303(1977).
   PubMed Web of Science ®Google Scholar
• Siscovick D , RaghunathanT, PsatyBet al.: Diuretic therapy for hypertension and the risk of primary cardiac arrest.N. Engl. J. Med.330, 1852–1857(1994).
   PubMed Web of Science ®Google Scholar
• Asfaha S , PadwalR: Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice.Curr. Hypertens. Rep.7, 314–322(2005).
   PubMed Web of Science ®Google Scholar
• Yusuf S , SleightP, PogueJ, BoschJ, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342, 145–153(2000).
   PubMed Web of Science ®Google Scholar
• Teo K , YusufS, AndersonCet al.: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.Am. Heart J.148, 52–61(2004).
   PubMed Web of Science ®Google Scholar
• Barnett AH , BainSC, BouterPet al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.N. Engl. J. Med.351, 1952–1961(2004).
   PubMed Web of Science ®Google Scholar
• Schmieder RE , DellesC, MimranA, FauvelJP, RuilopeL: Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in type 2 diabetes.J. Hypertens.23(Suppl. 2), S147 (2005).
   PubMed Web of Science ®Google Scholar
• Benson SC , PershadsinghHA, HoCIet al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity.Hypertension43, 993–1002(2004).
   PubMed Web of Science ®Google Scholar
• Schupp M , JankeJ, ClasenR, UngerT, KintscherU: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity.Circulation109, 2054–2057(2004).
   PubMed Web of Science ®Google Scholar
• Vitale C , MercuroG, CastiglioniCet al.: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.Cardiovasc. Diabetol.4, 1–8(2005).
   PubMed Web of Science ®Google Scholar
• Derosa G , RagonesiPD, MugelliniA, CiccarelliL, FogariR: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.Hypertens. Res.27, 457–464(2004).
   PubMed Web of Science ®Google Scholar
• Derosa G , CiceroAF, BertoneGet al.: Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.Clin. Ther.26, 1228–1236(2004).
   PubMed Web of Science ®Google Scholar

Websites

• Boehringer Ingelheim Pharmaceuticals Inc. Micardis (telmisartan) tablets 40 mg and 80 mg prescribing information bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Micardis+Tabs/MICARDIS20–40–80mg
   Google Scholar
• Boehringer Ingelheim. Micardis summary of product characteristics. European public assessment report www.emea.eu.int/humandocs/Humans/EPAR/micardis/micardisM.htm
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. Micardis HCT (telmisartan and hydrochlorothiazide) tablets, 40 mg/12.5 mg, 80 mg/12.5 mg and 80 mg/25 mg prescribing information bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Micardis+HCT/MicardisHCT-US2
   Google Scholar
• Boehinger Ingelheim. MicardisPlus summary of product characteristics. European public assessment report www.emea.eu.int/humandocs/Humans/EPAR/micardis/micardisM.htm
   Google Scholar